NCT06973174

Brief Summary

Background. Bacillus cereus group (Bc) comprises twenty-six closely related species of spore-forming environmental bacteria. Recently, increased sepsis and septic shock caused by Bc were reported in preterm neonates (PN), and the mortality rate can reach up to 30%. Using Whole Genome Sequencing (WGS) increasingly used to characterize Bc strains, The team aimed to determine an accurate identification to the species level of the strains involved in Bc invasive infections in preterm neonates in France and study their virulome profile.Methods. The team performed WGS for 40 neonate clinical strains responsible for invasive infections in PN. A screening of virulence genes was performed to characterize strains associated with poor prognosis. Clinical data were collected and all clinical and genomic findings were analyzed for risk factors for death. "

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
8mo left

Started Jan 2010

Longer than P75 for all trials

Geographic Reach
1 country

13 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress96%
Jan 2010Dec 2026

Study Start

First participant enrolled

January 1, 2010

Completed
15.4 years until next milestone

First Submitted

Initial submission to the registry

May 5, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 15, 2025

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2026

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2026

Last Updated

January 28, 2026

Status Verified

January 1, 2026

Enrollment Period

16.6 years

First QC Date

May 5, 2025

Last Update Submit

January 27, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mortality

    The mortality at D28 after birth was collected in patients record.

    28 days after birth

Interventions

The whole genome sequencing of the bacterial strains was performed by using both Illumina and Nanopore technologies, allowing us to obatin high quality and complete circular genomes.

Also known as: Bacterial species identification by Whole Genome sequencing

Eligibility Criteria

AgeUp to 143 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

The premature newborn included in the study were recruited from 14 NICU in 14 Tertiary Care center in France. This study is a national retrospective study

You may qualify if:

  • Premature newborn (i.e born before 37 last menstrual periods) with invasive infection caused by B. cereus (strains isolated from blood culture and cerebrsopinal fluid)

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

CHU NICE

Nice, Alpes Maritimes, 06000, France

RECRUITING

CHU lille

Lille, France

RECRUITING

AP-HM Marseille

Marseille, France

RECRUITING

CHU Nantes

Nantes, France

RECRUITING

CHU Nîmes

Nîmes, France

RECRUITING

AP-HP Hôpital Robert Debré

Paris, France

RECRUITING

Hôpital Antoine Béclère, AP-HP

Paris, France

RECRUITING

Hôpital Cochin

Paris, France

RECRUITING

CHU de Poitiers

Poitiers, France

RECRUITING

CHU Rennes

Rennes, France

RECRUITING

CHRU de Strasbourg

Strasbourg, France

RECRUITING

CHU Toulouse

Toulouse, France

RECRUITING

CHU de Tours

Tours, France

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Only the bacteial strains (isolated from patients blood culture samples were retained. Only bacterial DNA was extractable from these samples and not patient DNA.

MeSH Terms

Conditions

SepsisInfections

Condition Hierarchy (Ancestors)

Systemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 5, 2025

First Posted

May 15, 2025

Study Start

January 1, 2010

Primary Completion (Estimated)

July 30, 2026

Study Completion (Estimated)

December 30, 2026

Last Updated

January 28, 2026

Record last verified: 2026-01

Locations